8.350USD-2.79%Mkt Cap: 503.99M USDP/E: —Last update: 2026-06-01
Kyverna Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product…
Industry Peers
BiotechnologyIndicators:|
Key Statistics
Company
Market Cap503.99M USD
Enterprise Value315.28M USD
Revenue (TTM)—
Gross Profit-126.36M USD
Net Income (TTM)-161.31M USD
Revenue/Share—
Last Price8.350 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees130
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-2.88
PEG—
EV/EBITDA-1.95
EV/Revenue—
P/S—
P/B2.64
EPS (TTM)-3.27
EPS (Forward)-2.95
52W Range
2.47053% of range13.67
52W High13.67 USD
52W Low2.470 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-69.45%
ROA-54.90%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-153.71M USD
CapEx (TTM)1.13M USD
FCF Margin—
FCF Yield-18.60%
Net Debt-202.69M USD
Net Debt/EBITDA1.25
Balance Sheet
Debt/Equity0.12
Current Ratio8.15
Quick Ratio7.97
Book Value/Sh3.231 USD
Cash/Share3.889 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.3 (Strong Buy)
Target (Mean)30.40 USD
Target Range25.00 USD – 33.00 USD
# Analysts5
Ownership
Shares Out.60.80M
Float35.50M
Insiders7.07%
Institutions74.05%
Short Interest
Short Ratio4.1d
Short % Float10.24%
Short % Out.8.69%
Shares Short5.28M
Short (prev mo.)4.23M
Technical
SMA 509.039 (-7.6%)
SMA 2007.532 (+10.9%)
Beta2.06
S&P 52W Chg27.94%
Avg Vol (30d)1.16M
Avg Vol (10d)909.03K
Technical Indicators
RSI (14)44.5
MACD-0.1711
MACD Signal-0.0536
MACD Hist.-0.1175
BB Upper10.72 USD
BB Middle9.226 USD
BB Lower7.735 USD
BB Width32.31%
ATR (14)0.6839 USD
Vol Ratio (20d)0.50x